Description
EORTC Lung Cancer Group has a strong track record in initiating and conducting clinical trials across thoracic cancers. The focus is not only lung cancer but also mesothelioma and thymomas. This follows EORTC strategy to challenge, re-define and develop standards of care for loco-regional as well as for systemic treatments.
Scientific projects are designed and conducted to integrate disciplines such as imaging, translational research, quality of life and quality assurance. There are multiple partnerships, especially with national groups in Europe but also with international umbrella organisations. The group places special emphasis on recruiting and mentoring junior colleagues who are interested in pursuing an academic career in the field of thoracic oncology.
Projects testing the place of immunotherapy in the treatment of lung cancer are also ongoing such as addressing the role of immunotherapy in the adjuvant setting of lung cancer.
Related News
All newsRecruiting Clinical Trials
All clinical trials in this research field-
Phase 2
Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomized phase II study of the EORTC Lung Cancer Group
-
Phase 2
EORTC randomized phase II study of pleurectomy/ decortication (P/D) preceded or followed by chemotherapy in patients with early stage malignant pleural mesothelioma
-
Phase 2-3
Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours
-
Phase 2
Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor
Main Achievements
EORTC has contributed to changing the standards of care for thoracic oncology:
Established radiotherapy as the preferred loco-regional treatment in non-small-cell lung cancer patients. &
Demonstrated the benefit of prophylactic cranial irradiation to reduce the incidence of symptomatic brain metastases in extensive small-cell lung cancer.
Confirmed a combination of Cisplatin and Raltitrexed was more effective than Cisplatin alone in improving the survival of patients with Malignant Pleural Mesothelioma (MPM).
Related Projects
- 1459: Exploratory analysis of the pleural mesothelioma genome by next generation sequencing
- 1495: Update of OS in 08092 and CRP marker
- 1496: Survey on Thymoma / thymic malignancy
- 1549: Pharmacogenetic analysis from the double blind randomized phase III study ofmaintenance pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung Group study
- 1557 Predict therapy in NSCLC: Studying changes in the expression of genes related to the metabolism and the chemotherapeutic activity in primary tumor and lymph and mediastinal lymph nodes infiltrated in resectable NSCLC
- 1638: Phase II, Parallel-Arm Study of MGCD265 in patients with locally advanced or metastatic NSCLC with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
IMI CANCER-ID – Cancer treatment and monitoring through identification of circulating tumor cells and tumor related nucleic acids in blood. EORTC is contributing with biological material and related data from EORTC study 1335 SPECTAlung.
European Reference Networks (ERN) for rare solid tumours (EURACAN). EURACAN is involving references centers in Europe covering ten types of rare cancers. EURACAN will improve patient cares and facilitate research in rare cancers. EORTC is providing the clinical research infrastructure. (No website available yet)
Research Group
Group documents-
Chair
Anne-Marie Dingemans
Erasmus MC Rotterdam
Rotterdam, Netherlands
-
Secretary
Jordi Remon Masip
HM Delfos Hospital-CIOCC
Barcelona, Spain
-
Treasurer
Thierry Berghmans
Institut Jules Bordet
Brussels, Belgium
Other members
-
C. Faivre-Finn - Manchester, GB
Early stage NSCLC & Radiotherapy
The Christie NHS Foundation Trust
-
J. Edwards - Sheffield , GB
Early stage NSCLC & Surgery
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital
-
M. Reck - Grosshansdorf, DE
Metastatic NSCLC
Hospital Grosshansdorf
-
L. Greillier - Marseille, FR
Malignant Pleural Mesothelioma
Assistance Publique - Hopitaux de Marseille - Hopital Nord
-
S. Lantuejoul - Grenoble, FR
Pathology & TR
CHU de Grenoble - Departement d'Anatomie et Cytologie Pathologiques
-
S. Novello - Orbassano, IT
SCLC
Ospedale S. Luigi Gonzaga - Universita Di Torino
-
N. Girard - Paris, FR
Thymic malignancies
Institut Curie
-
M. O'Brien - Sutton, GB
Past Chair
Royal Marsden Hospital
-
J. Menis - Padova, IT
Young investigator lead
IRCCS - Istituto Oncologico Veneto
-
M. Giaj Levra - Grenoble, FR
Young investigator secretary
CHU de Grenoble - La Tronche - Hopital A. Michallon
Notable Publications
All publications on this research field-
2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
-
2020
Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study
-
2020
Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials
-
2019
Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report
-
2019
Defining oligometastatic non-small cell lung cancer: a simulated multidisciplinary expert opinion